What is the price target for XLRN stock?
17 analysts have analysed XLRN and the average price target is 182.68 null. This implies a price increase of 2.2% is expected in the next year compared to the current price of 178.75.
Acceleron Pharma (XLRN) Forecast, Price Target & Analyst Ratings
NASDAQ:XLRN
Current stock price
178.75
-0.93 (-0.52%)
At close:
179.92
+1.17 (+0.65%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Acceleron Pharma (XLRN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Feb 28, 2022
- Period
- Q4 / 2021
- EPS Estimate
- -$0.91
- Revenue Estimate
- 45.41M
Price Target Details & History
Consensus Price Target and Range
Mean target
$182.68
Upside
+ 2.20%
From current price of $178.75 to mean target of $182.68, Based on 17 analyst forecasts
Low
$172.71
Median
$183.60
High
$189.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
17 Wall Street analysts provided a forecast for the next 12 months for XLRN. The average price target is 182.68 null. This implies a price increase of 2.2% is expected in the next year compared to the current price of 178.75.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.94%
XLRN was analyzed by 17 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about XLRN.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
XLRN was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-10-07 | Jefferies | Initiate | Hold |
| 2021-10-04 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2021-10-01 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2021-10-01 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2021-10-01 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-30 | SVB Leerink | Maintains | Market Perform |
| 2021-09-30 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2021-09-30 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-09-27 | RBC Capital | Maintains | Sector Perform |
| 2021-03-23 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |
| 2021-03-01 | Citigroup | Maintains | Buy |
| 2021-02-26 | SVB Leerink | Maintains | Outperform |
| 2021-02-26 | Morgan Stanley | Maintains | Overweight |
| 2021-02-26 | Piper Sandler | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Feb 28, 2022
- Period
- Q4 / 2021
- EPS Estimate
- -$0.91
- Revenue Estimate
- 45.41M
- Revenue Q2Q
- 75.53%
- EPS Q2Q
- 4.57%
- Number of Analysts
- 15
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
XLRN is expected to report earnings on 2/28/2022. The consensus EPS estimate for the next earnings is -0.91 null and the consensus revenue estimate is 45.41M null.
Full Analyst Estimates 2021 - 2025
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.99M 3.78% | 73.99M 428.88% | 92.52M 25.04% | 139.562M 50.85% | 215.155M 54.16% | 302.159M 40.44% | 436.356M 44.41% | 642.756M 47.30% | |
| EBITDA YoY % growth | -120.66M -12.61% | -132.51M -9.82% | -163.46M -23.36% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -124.41M -13.12% | -136.45M -9.68% | -167.31M -22.62% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | -889.28% | -184.42% | -180.84% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -2.59 0.77% | -2.38 8.11% | -2.90 -21.85% | -4.11 -41.56% | -3.39 17.52% | -2.12 37.48% | -2.65 -25.00% | -3.37 -27.50% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.91 4.57% | -1.02 3.18% | -0.95 9.33% | -0.84 27.72% | -0.71 21.92% | -1.01 0.67% | -0.85 11.07% | -0.87 -3.41% | -0.43 39.48% |
| Revenue Q2Q % growth | 45.41M 75.53% | 42.653M 72.27% | 49.215M 76.14% | 54.308M 58.80% | 62.88M 38.47% | 56.1M 31.53% | 69.564M 41.35% | 72.522M 33.54% | 107.61M 71.14% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
8.29%
EPS Next 5 Year
-3.07%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
45.08%
Revenue Next 5 Year
45.39%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Acceleron Pharma / XLRN Forecast FAQ
Can you provide the upcoming earnings date for Acceleron Pharma?
Acceleron Pharma (XLRN) will report earnings on 2022-02-28, after the market close.
What are the consensus estimates for Acceleron Pharma (XLRN) next earnings?
The consensus EPS estimate for the next earnings of Acceleron Pharma (XLRN) is -0.91 null and the consensus revenue estimate is 45.41M null.
Can you provide the expected long term growth rate for Acceleron Pharma stock?
The expected long term growth rate for Acceleron Pharma (XLRN) is 45.08%.